Preclinical Imaging Market Global Size, Share, Key Players,...

Preclinical Imaging Market Global Size, Share, Key Players, Production, Growth and Future Insights

Posted 2024-02-15 15:36:59

According to a new report published by K D Market Insights, titled, “Preclinical Imaging Market Insights, Trends, Opportunity & Forecast, 2023–2032,” the global preclinical imaging market size is anticipated to witness moderate growth during the forecast period i.e., 2023-2032. The rapid technological advancements in molecular imaging, the increasing demand for non-invasive small animal imaging techniques, and the growing support from public-private initiatives and funding for preclinical research which are the major factors augmenting the growth of the global preclinical imaging market.

Significant investments and funding in research and development initiatives have spurred the market's expansion. These investments aim to push the boundaries of molecular imaging, fostering the development of cutting-edge imaging systems are further expected to create ample growth opportunities for the global preclinical imaging market during the forecast period i.e., 2023-2032. Moreover, the increasing demand for non-invasive small animal imaging techniques, has propelled market expansion. Growing emphasis on preclinical research, backed by both private and public organizations, is expected to contribute towards the market growth during the period.

The North America region accounted for the largest share in the global preclinical imaging market in 2022. The region is further projected to continue dominating in the market and also register the highest CAGR in the market during the forecast period. This can be attributed to the by robust R&D infrastructure for life science research, fast adoption of novel molecular imaging technologies, and a significant presence of pharmaceutical and biotechnology companies.

According to modality, the optical imaging systems segment accounted for the largest market share in the preclinical imaging market in 2022 and is further expected to continue with the trend during the forecast period i.e., 2023 – 2032.

The global preclinical imaging market is segmented into modality, reagents, end user and region. Based on modality, the market is bifurcated into optical imaging, nuclear imaging, micro-MRI systems, micro-ultrasound systems, micro-CT systems, photoacoustic imaging, magnetic particle imaging. Based on reagents, it is classified into optical imaging reagents, nuclear imaging reagents, MRI contrast agents, ultrasound contrast agents, CT contrast agents. Based on end user, it is classified into pharmaceutical companies, biotechnology companies, research institutes.

The global preclinical imaging market is analyzed across North America (U.S. & Canada), Europe (Germany, United Kingdom, France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Indonesia, Thailand, Australia, New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and the Rest of Latin America) and Middle East & Africa (GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, and Rest of Middle East & Africa).

Key Insights of Preclinical imaging Market

On the basis of modality, the optical imaging systems segment accounted for the largest market share in the preclinical imaging market in 2022 and is further expected to continue with the trend during the forecast period i.e., 2023 – 2032.
On the basis of region, North America accounted for the largest share in the global preclinical imaging market in 2022. The region is further projected to continue dominating in the market during the forecast period.
On the basis of region, Asia-Pacific is estimated to account for the second largest share in the market during the forecast period.

Some of the major preclinical imaging companies profiled in the report include PerkinElmer, Inc., Bruker Corporation, FUJIFILM Holdings Corporation, Mediso Ltd., MILabs B.V., MR Solutions, LI-COR Biosciences, Aspect Imaging, TriFoil Imaging and Miltenyi Biotech GmbH.